MiMedx Group Inc Common Stock
MDXGUnited States
5 filed reports · 298 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 761 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 821 | Dec 2025 |
Financial data
298 concepts · 1,582 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial291 concepts · 1,546 facts · Dec 2023 to Jun 2026
- Allowance for doubtful accounts receivable current14 · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Provision for doubtful accounts13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Allowance for doubtful accounts receivable write offs12 · Mar 2024 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest income expense nonoperating net12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)11 · Dec 2023 to Mar 2026
- Increase decrease in accounts payable11 · Dec 2023 to Jun 2026
- Increase decrease in accounts receivable11 · Dec 2023 to Jun 2026
- Increase decrease in accrued liabilities11 · Dec 2023 to Jun 2026
- Increase decrease in deferred income taxes11 · Dec 2023 to Jun 2026
Product1 concepts · 24 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
Segment6 concepts · 12 facts · Jun 2025 to Jun 2026
- General and administrative expense (US GAAP)2 · Jun 2025 to Jun 2026
- Interest expense nonoperating2 · Jun 2025 to Jun 2026
- Interest income expense nonoperating net2 · Jun 2025 to Jun 2026
- Investment income interest2 · Jun 2025 to Jun 2026
- Selling and marketing expense (US GAAP)2 · Jun 2025 to Jun 2026
- Selling general and administrative expense2 · Jun 2025 to Jun 2026
Segments
36 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service2 members · 24 facts
- Surgical12 · Dec 2023 to Jun 2026
- Wound12 · Dec 2023 to Jun 2026
Statement business segments1 member · 12 facts
- Reportable12 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Jul 2025 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Oct 29, 2025
- FY2025 Q2Jul 30, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.